PTEN and prostate adenocarcinoma: To validate our PTEN loss signatures in an independent cohort, we next examined the TCGA PRAD cohort [36], where PTEN status was estimated by genomic copy number (CN) assessment, which was closely aligned with PTEN gene expression (Figure S2).